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studies typically evaluate whether extra sparing affects 
boost/elective planning target volume (PTVB/PTVE) dose 
coverage or homogeneity, sparing of previously included 
OARs or dose conformity. However, once novel techniques 
are introduced in routine clinical practice, predicted changes 
are rarely retrospectively evaluated or confirmed. We 
therefore analyzed longitudinal changes in plan quality for 
head and neck cancer (HNC) patients treated at our 
department from 2005-2015 following the introduction of 
new technologies and planning techniques. 
 
Material and Methods: 4x30 plans of oropharynx patients 
were selected from 4 distinct periods (P). P1: 7-field static 
IMRT plans with parotid gland sparing. P2: Dual arc VMAT 
plans including submandibular gland sparing. P3: VMAT with 
swallowing muscle sparing and further attempts to reduce 
parotid gland / oral cavity doses through manual interactivity 
during optimization. P4: VMAT with the same OARs as P3, but 
automatically optimized using in-house developed software. 
PTVE prescribed doses were 54.25-57.75Gy in P1/P2, and 
54.25Gy in P3/P4. 70Gy was prescribed to PTVB for all 
patients, delivered in 35 fractions as a simultaneous 
integrated boost. Plans were compared using mean dose to 
composite salivary glands (Dsal), swallowing muscles (Dswal) 
and oral cavity (Doc), PTVB/PTVE dose coverage (V95) and 
homogeneity indices (HI), and V5Gy (volume receiving 5Gy), 
V30Gy, V50Gy and mean dose to the body contour with PTV 
subtracted. 
 
Results: The Figure shows mean salivary gland, swallowing 
muscle and oral cavity DVHs for each period and the Table 
summarizes the mean dosimetric results. OAR sparing, 
swallowing muscle sparing in particular (P1=55.0Gy to 
P4=38.6Gy), gradually improved throughout the periods 
without compromising PTV dose coverage, homogeneity or 
conformity indexes. In addition, P3 improved Dsal/Doc over 
P2 by 6.3/7.5Gy, illustrative of gains facilitated by improved 
planner experience and planning technique used. 
Automatically optimized plans (P4) achieved similar OAR 
sparing, Body-PTV doses and PTV V95/HI values as P3 plans. 
Although depending on the degree of OAR-PTV overlap, 
individual OAR sparing could vary between the periods, such 
differences are inherent to this type of study. 
 
 
 
 
Conclusion: Successive improvements in radiotherapy 
technologies and planning techniques substantially improved 
HNC plan quality. Swallowing muscle sparing did not 
compromise sparing of other OARs, PTV dose coverage and 
homogeneity or dose deposition in the remainder of the 
body. On the contrary, salivary gland doses, HIB/HIE and 
Body-PTV doses generally decreased in P3/P4 compared to 
earlier periods.  
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Purpose or Objective: In this study, we aimed to compare 
the effect of 4D mid-ventilation vs. free breathing 3D CT 
technique on target volume differences and corresponding 
dosimetrical changes using intensity modulated radiation 
therapy (IMRT) for patients with locally advanced non small 
cell lung cancer (NSCLC). Furthermore, additional 
investigation was performed to evaluate the possible 
dosimetrical improvement by using volumetric modulated 
arctherapy (VMAT) instead of IMRT. 
 
Material and Methods: Twenty-three patients with locally 
advanced NSCLC were scanned with 4D-CT acquisition for 
treatment planning purpose. The different breathing phases 
were analyzed to obtain the tumor motion (direction and 
amplitude) and to determine which dataset better represents 
the mid-ventilation phase. Based on the gross tumor volume, 
two planning target volumes were generated for each 
patient: One using 15 mm margin in all three directions (PTV-
3D) and the other with 12 mm with the margin of 1/4 of the 
movement (= mid-ventilation approach, PTV-4D). For 
objective comparison, IMRT plans (3D-IMRT, 4D-IMRT) were 
made by using Pinnacle v9.0 (Philips, Eindhoven, the 
Netherlands) with identical optimization parameters. For the 
4D mid-vent, additional VMAT plan was generated. All DVH 
were collected using the VODCA package (Medical Software 
Solutions, Hagendorn, Switzerland). For the evaluation, the 
following dosimetric parameters were used: for 
corresponding PTV coverage using V95%, for lungs-PTV4D (for 
objective comparison of healthy lung volume) V20Gy and 
Dmean, for spinal cord Dmax, for oesophagus Dmean, while 
for heart V35Gy. All 4D plans were verified at the treatment 
machine following the institutions QA procedure. Differences 
were tested using the pairwise t-tests with the significance 
level of p<0.05. 
 
Results: Based on the 4D-CT analysis, the average (range) 
tumor motions were 3.1 (0-11.2) mm for cranio-caudal, 1.7 
(0-4.6) mm for antero-posterior and 1.9 (0-4.0) mm for 
lateral direction. The average PTV volumes were reduced on 
average with 14% (Table 1).  
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All treatment plans were met the clinically acceptable goals. 
The 4D-IMRT showed a statistically significant improvement 
(p<0.05) compared to 3D-IMRT in all relevant parameters. 
The 4D-VMAT plans further reduced all OAR parameters 
significantly (p<0.05), while maintaining identical target 
coverage. Phantom measurements confirmed that both 
techniques (IMRT and VMAT) can be safely administered.  
 
Conclusion: By using the 4D-CT acquisition and mid-
ventilation target delineation approach, significant PTV 
volume reduction was obtained. This method is improving 
PTV coverage and OAR doses using the same technique 
(IMRT). VMAT technique might further gain additional 
dosimetric benefits for patients with NSCLC.  
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Purpose or Objective: We applied a variety of published 
conventional and stereotactic plan quality dosimetric indices 
to describe and discern clinically achieved target dose 
distributions in Lung SBRT. 
 
Material and Methods: Treatment plans of 100 Lung SBRT 
patients treated were retrospectively reviewed. The targets 
(n=102) were evenly distributed – right lung (53) and left lung 
(49). Patients were prescribed to a total dose of 50-60 Gy in 
3-5 fractions. Dose optimizations were accomplished with 6 
MV using either 2-5 arcs VMAT (90); 8-14 IMRT fields (6) or 10-
16 static fields (6). Dose calculations were performed using 
AAA algorithm with heterogeneity correction. A literature 
review on dosimetric indices recommended for qualitative 
analyses of conventional and stereotactic dose distributions 
in target coverage, homogeneity, conformity and gradient 
categories was performed. From each patient treatment 
plan, the necessary parameters for calculating various indices 
were quantified. 
 
Results: For the study, the mean (±SD) values for indices 
were: coverage (96.4 (±2.4) %); homogeneity (1.27 (±0.07)); 
Conformity (1.04 (±0.08)) and Gradient 1.27(±0.30) cm). 
Geometric conformity (g) strongly correlated with the 
conformity index (defined by van’t Riet /Paddick)(p<0.0001). 
All Gradient measures strongly correlated with PTV 
(p<0.0001). Evaluating High Dose Spillage, the average 
cumulative volume of all tissue outside the PTV receiving a 
dose of > 105% of prescription dose was 0.94 (± 1.64) %. 
Considering Low Dose Spillage, the maximum % of 
prescription dose to any point at 2 cm distance in any 
direction from PTV was 56.0 (± 11.4) %. The lung volume 
(total lung volume – GTV) receiving doses of 20 Gy and 5 Gy 
(V20 and V5) were mean 4.9 % (± 3.1) and 16.9 % (± 9.0). The 
RTOG lung SBRT protocol advocated conformity guidelines for 
prescribed dose in all dosimetric evaluation categories were 
met in ≥94% of cases.  
 
Conclusion: The high-rate of adherence to RTOG protocol 
dose conformancy guidelines in our study validates that 
indices derived from our SBRT lung plan dose distributions 
are a tool for establishing plan metrics in clinical trials, for 
scoring competing plans and as well as for comparing inter-
institutional lung SBRT plan dosimetric data. However, these 
indices should only be used as an additional tool to grade 
plan quality once a satisfactory treatment plan has been 
achieved judged on the basis of clinical expertise, acceptable 
dose distributions and dose gradients, while respecting 
critical organ and normal structure doses. 
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Purpose or Objective: Improvements in overall survival of 
pancreatic cancer patients after carbon ion radiotherapy 
have been reported from Japanese clinical trials. Due to the 
sharp distal dose fall-off, a high dose can be delivered to the 
tumor, while sparing the nearby healthy organs. However, 
changes in gastrointestinal gas volumes can greatly influence 
the carbon ion range. 
We evaluated the robustness of carbon ion therapy for 
pancreatic cancer patients by investigating the impact of 
interfractional anatomical changes on the accumulated dose 
when using bony anatomy- and fiducial marker-based position 
verification. 
 
Material and Methods: Nine pancreatic cancer patients, 
treated with photon radiotherapy in free breathing, were 
included in this retrospective planning study. The internal 
gross tumor volume (iGTV), internal clinical target volume 
(iCTV), duodenum, stomach, liver, spinal cord and kidneys 
were delineated on the (average) 4D-CT scan. Intratumoral 
gold fiducial markers were implanted in all patients to enable 
position verification using cone beam CT (CBCT). 
Treatment plans were created using a 4-beam passive 
scattering technique. A smearing technique was used to 
account for patient setup errors; a safety margin of 3 mm 
was applied to compensate for range uncertainties. Plans 
were generated to deliver at least 95% of the prescribed dose 
(36GyE in 12 fractions) to 99% of the iCTV. 
To enable dose calculations on the daily CBCTs, the planning 
CT was deformably registered to each CBCT. The 
gastrointestinal gas volume visible on each CBCT was copied 
to the deformed CTs. Next, fraction doses were calculated by 
aligning the treatment plan according to a bony anatomy- 
and a fiducial marker-based registration. For both 
registration methods the resulting fraction doses were rigidly 
summed to acquire the accumulated dose. 
We compared both accumulated doses to the planned dose 
using dose-volume histograms (DVHs) and calculated DVH 
parameters for the iGTV and iCTV (Dmean, D2%, D98%) and 
organs at risk (Dmean, D2cc). 
 
Results: The D98% of the target volumes showed the largest 
differences (Figure). For the bony anatomy-based 
registration, D98% reduced significantly from 99.6% ± 0.2% 
(iGTV; mean ± standard deviation) and 98.6% ± 0.5% (iCTV) as 
planned to 92.3% ± 3.8% and 81.9% ± 7.7% for the 
accumulated dose, respectively. For the marker-based 
registration, this was slightly improved to 95.1% ± 4.0% (iGTV) 
and 88.6% ± 4.0% (iCTV), which was still significantly 
different from planned. 
For the duodenum, severe deviations were observed in the 
DVHs between the planned and accumulated dose. Both the 
direction and magnitude of the deviations differed 
considerably between patients. The other organs showed 
minor changes. 
